Richard Buka @richardbuka.bsky.social · 09/03/2025The latest episode of Don't Just Read the Abstract with is now up! We discuss the APPOINT-PNH trial of ictacopan, a proximal complement inhibitor and the first oral therapy for PNH. Available now on all podcast platforms. 000
Richard Buka @richardbuka.bsky.social · 05/03/2025Hugely excited for this webinar from Saskia Middledorp lead on sooo many pivotal studies in H&T. Part of HaemSTAR's research-focused 2 monthly webinar series hosted by the limbic Tues 25th March 08:15 - 09:00 GMT. thelimbic.com/uk/haematolo... 010
Reposted by Richard BukaSaskia Middeldorp @middeldorps.bsky.social · 08/02/2025We have te remain vigilant on scientific fraud. It seems quite frequent in women’s health 😢 One way to mitigate this would be having more 👀 in multicenter studies retractionwatch.com/2025/01/24/p...retractionwatch.comPaper retracted after author told journal study was ‘not actually performed’Nearly 20 years after the publication of a paper on phytoestrogens in postmenopausal women, one of the authors said the study had never been performed, according to a recently published retraction … 1124
Richard Buka @richardbuka.bsky.social · 07/02/2025Extremely interesting! Antibodies against COVID-19 receptor binding domain are also anti-PF4/heparin antibodies - frequently platelet activating. 1st report I know of showing this phenomenon. Well done to authors @versitiresearch.bsky.social, reviewers, & editors @bloodportfolio.bsky.social 030
Richard Buka @richardbuka.bsky.social · 03/02/2025**NEW EPISODE** Pleased to release the latest episode of Don't Just Read the Abstract with Pip Nicolson. We discuss Kuhne et al.'s study in @bloodportfolio.bsky.social on the treatment of TTP without the use of plasma exchange. There will be a follow-up episode with an author interview. 040
Richard Buka @richardbuka.bsky.social · 28/01/2025Very cool study in @nature.com showing transfer of mutated mitochondria from cancer cells into tumour infiltrating T cells --> impaired T cell function and association with poor response to checkpoint inhibition. www.nature.com/articles/s41... 010
Richard Buka @richardbuka.bsky.social · 07/01/2025Pleased to share this perspective on andexanet alfa, now published in @rpth.bsky.social #openaccess🔓 rpthjournal.org/article/S2475-… I cover blinding, surrogate endpoints, clinical outcomes and thrombosis. A brief 🧵 121
Richard Buka @richardbuka.bsky.social · 12/12/2024Making a mirror image of organisms doesn't sound like a good idea... Organisms made out of left handed DNA and right handed amino acids could evade our immune systems and have profound effects on the survival of life on earth. www.science.org/doi/10.1126/...science.orgConfronting risks of mirror lifeBroad discussion is needed to chart a path forward. 000
Richard Buka @richardbuka.bsky.social · 09/12/2024Sitting at the front for the Ernest Butler prize lectures at #ASH24. Spent last 10 reading about this remarkable physician scientist who discovered G6PD deficiency, X inactivation, Gaucher disease, pioneered BMT and coded reference manager software en.m.wikipedia.org/wiki/Ernest_... 150
Reposted by Richard BukaBen Samelson-Jones, MD, PhD @samelsonjones.bsky.social · 07/12/2024#Ash24 #hemesky Very large datasets suggest factor 12 haploinsufficiency substantially reduce venous #thrombosis. Suggest intravascular pathological clot formation is molecularly different than extra vascular hemostatic clot formation? 162
Reposted by Richard BukaInternational Society on Thrombosis and Haemostasis @isth.org · 03/12/2024Abstract submission for #ISTH2025 is OPEN! Tag someone who should definitely submit an abstract below⏬ 052
Reposted by Richard BukaProfMakris @profmakris.bsky.social · 28/11/2024A large prospective study from Austria shows that bleeding is more frequent and is of more relevance than generally assumed. Paper is behind a pay wall. tinyurl.com/2tf8kfv6 #cancer #bleeding 153
Richard Buka @richardbuka.bsky.social · 28/11/2024The other day, I summarised the new data on thrombotic events with andexanet alfa, presented to/by the FDA. Now, let's focus on new efficacy data A🧵 100
Richard Buka @richardbuka.bsky.social · 25/11/2024Tons of NEW DATA about andexanet, presented as part of FDA hearing last week. If you couldn’t make it through the short 6h meeting, GOOD NEWS, I’ve watched it and highlighted the important points. A🧵 195
Reposted by Richard BukaShematologist, MD @shematologist.medsky.social · 21/11/2024Recent Danish study of 569k individuals presented at AHA scientific sessions found poor oral health in children to be associated with increased risk of ischemic heart disease, myocardial infarction, and ischemic stroke in adulthood. Just one more reason that fluoride in our water is a good idea. 1015428
Richard Buka @richardbuka.bsky.social · 21/11/2024Very much enjoying my first couple of days on Bsky! Lovely interface and healthy interactions. Social media for the good of humanity rather than profit or some other nefarious goal. Still on X for the moment but will post on both. The switching moat is wide and deep! 030
Richard Buka @richardbuka.bsky.social · 20/11/20241/ FDA hearing on #andexanet alfa is tomorrow (21 Nov 2024). The documents contain some more data on thrombotic events that weren't published in ANNEXA-I. To be honest, reading through, I have found this data pretty shocking. A 🧵 173